Protective efficacy of a live attenuated vaccine against argentine hemorrhagic fever

Julio I. Maiztegui, Kelly T. McKee, Julio G.Barrera Oro, Lee H. Harrison, Paul H. Gib, Maria R. Feuillade, Delia A. Enria, Ana M. Briggile, Silvana C. Levis, Ana M. Ambrosio, Neal A. Halsey, Clarence J. Peters

Research output: Contribution to journalArticlepeer-review

Abstract

Argentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF- endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82%-99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60%-94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalJournal of Infectious Diseases
Volume177
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Protective efficacy of a live attenuated vaccine against argentine hemorrhagic fever'. Together they form a unique fingerprint.

Cite this